Functional Role and Therapeutic Potential of the Pim-1 Kinase in Colon Carcinoma  by Weirauch, Ulrike et al.
Functional Role and Therapeutic
Potential of the Pim-1 Kinase
in Colon Carcinoma1,2
Ulrike Weirauch*,†, Nadine Beckmann*,†,
Maren Thomas‡, Arnold Grünweller‡,
Kilian Huber§, Franz Bracher§,
Roland K. Hartmann‡ and Achim Aigner*,†
*Rudolf Boehm Institute for Pharmacology and
Toxicology, Clinical Pharmacology, University of Leipzig,
Leipzig, Germany; †Pharmacological Institute,
Philipps University Marburg, Marburg, Germany; ‡Institute
of Pharmaceutical Chemistry, Philipps University Marburg,
Marburg, Germany; §Department of Pharmacy, Center for
Drug Research, Ludwig Maximilians University Munich,
Munich, Germany
Abstract
PURPOSE: The provirus integration site for Moloney murine leukemia virus 1 (Pim-1) kinase is overexpressed in
various tumors and has been linked to poor prognosis. Its role as proto-oncogene is based on several Pim-1 target
proteins involved in pivotal cellular processes. Here, we explore the functional relevance of Pim-1 in colon carcinoma.
EXPERIMENTAL DESIGN: RNAi-based knockdown approaches, as well as a specific small molecule inhibitor, were
used to inhibit Pim-1 in colon carcinoma cells. The effects were analyzed regarding proliferation, apoptosis, sensiti-
zation toward cytostatic treatment, and overall antitumor effect in vitro and in mouse tumor models in vivo. RESULTS:
We demonstrate antiproliferative, proapoptotic, and overall antitumor effects of Pim-1 inhibition. The sensitization to
5-fluorouracil (5-FU) treatment upon Pim-1 knockdown offers new possibilities for combinatorial treatment ap-
proaches. Importantly, this also antagonizes a 5-FU–triggered Pim-1 up-regulation, which is mediated by decreased
levels of miR-15b, a microRNA we newly identify to regulate Pim-1. The analysis of the molecular effects of Pim-1
inhibition reveals a complex regulatory network, with therapeutic Pim-1 repression leading to major changes in onco-
genic signal transduction with regard to p21Cip1/WAF1, STAT3, c-jun-N-terminal kinase (JNK), c-Myc, and survivin and
in the levels of apoptosis-related proteins Puma, Bax, and Bcl-xL. CONCLUSIONS:We demonstrate that Pim-1 plays
a pivotal role in several tumor-relevant signaling pathways and establish the functional relevance of Pim-1 in colon car-
cinoma. Our results also substantiate the RNAi-mediated Pim-1 knockdown based on polymeric polyethylenimine/
small interfering RNA nanoparticles as a promising therapeutic approach.
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Introduction
Provirus integration site for Moloney murine leukemia virus 1 (Pim-1)
kinase belongs to a family of constitutively active serine/threonine
kinases [1,2]. The expression of Pim-1 is controlled on the transcriptional
level by several interleukins and growth factors through the Jak/STAT
pathway involving STAT3 and/or STAT5 [3,4]. Additionally, its expres-
sion can be increased upon cellular stress like hypoxia [5] or shear stress
[6]. Only recently, we have identified Pim-1 as target of miR-33a,
indicating a posttranscriptional regulation of Pim-1 by microRNAs
(miRNAs) [7,8]. On the protein level, the stability of Pim-1 is regu-
lated by Hsp90, Hsp70, and the ubiquitin-proteasome pathway [9].
Several target proteins of Pim-1 involved in apoptosis, cell cycle reg-
ulation, signal transduction pathways, and transcriptional regulation
have been identified, which are overall linked to cell survival (see,
e.g., [10,11]). Furthermore, Pim-1 has been shown to act synergistically
with the oncogenic transcription factor c-Myc by phosphorylation/
stabilization of c-Myc [12] and by interaction with c-Myc on the
chromatin level, leading to elevated transcription of c-Myc target genes
[13]. The overexpression of Pim-1 can thus substantially contribute
to malignant transformation of cells during tumorigenesis ([14]; for
review, see [15]), establishing Pim-1 as a proto-oncogene. In several
tumor entities, e.g., B-cell lymphoma, prostate cancer, colorectal cancer,
or pancreatic cancer, an overexpression of Pim-1 has been described and
linked to poor prognosis (for review, see [16]). In hematopoietic malig-
nancies and prostate cancer, Pim-1 is known to promote tumor onset
and progression [16,17], and Pim-1 knockdown or inhibition led to
antitumor effects [18,19]. In colon carcinoma, Pim-1 is overexpressed
[18,19], but the functional relevance of Pim-1 has not been determined.
Colon carcinoma is the third most common form of cancer and the
second leading cause of cancer-related death in the Western world.
Despite a favorable prognosis when detected at early stages, the pres-
ence of metastatic disease is associated with limited survival, indicating
the need for novel molecular targets and strategies to specifically block
oncogenic pathways.
In this study, we establish the functional relevance of Pim-1 in
colon carcinoma. Using RNAi-based knockdown approaches as well
as a specific low molecular weight inhibitor, we demonstrate antitumor
effects in vitro and in vivo, analyze the cross talk between Pim-1 and
the established cytostatic 5-fluorouracil (5-FU), and determine the
effects of Pim-1 inhibition on downstream signal transduction path-
ways relevant for proliferation or apoptosis.
Materials and Methods
Cell Culture and Transfection
Colon carcinoma cell lines HCT-116, LS174T, and HT29 were
purchased from the American Type Culture Collection (Manassas, VA)
and authenticated by the vendor. Cells were maintained in a humidified
incubator under standard conditions (37°C, 5% CO2) in Iscove’s
modified Dulbecco’s medium (IMDM; PAA, Cölbe, Germany) sup-
plemented with 10% fetal calf serum (FCS).
SiRNAs were purchased from Thermo Scientific (Schwerte,
Germany); miR-15b sense and antisense strands were purchased from
Eurofins MWG Operon (Ebersberg, Germany). Cells were transfected
with small interfering RNA (siRNA) targeting Pim-1 [siPim-1: 5′-GGA
ACA ACA UUU ACA ACU CdTdT (sense) and 5′-GAG UUG UAA
AUG UUG UUC CdTdT (antisense)] or negative control siRNA,
targeting luciferase mRNA [siCtrl: 5′-CUU ACG CUG AGU ACU
UCG AdTdT (sense) and 5′-UCG AAG UAC UCA GCG UAA
GdTdT (antisense)], or targeting enhanced green fluorescent protein
(eGFP) [siEGFP: 5′ GCA GCA CGA CUU CUU CAA GdTdT 3′
(sense) and 5′CUUGAAGAAGUCGUGCUGCdTdT3′ (antisense)],
or with miR-15b (mature miR-15b sequence, miRBase accession
MI0000438). For annealing of the miRNA, sense and antisense
strands were dissolved equimolarly in annealing buffer, heated to
95°C for 5 minutes, and cooled down slowly to room temperature.
For transfection, 2 × 102 (HCT-116 and HT29) or 1 × 103
(LS174T) cells were seeded in a 96-well plate, 7 × 104 cells in a 24-well
plate, or 3.5 × 105 cells in a 6-well plate, respectively, and incubated
under standard conditions unless stated otherwise. SiRNA (20 nM)
was transfected using either INTERFERin siRNA transfection re-
agent or jetPRIME transfection reagent (Peqlab, Erlangen, Germany)
according to the manufacturer’s protocol and incubated for the indi-
cated time periods. Transfection of plasmid DNA was performed using
FuGENE HD Transfection Reagent (Roche, Penzberg, Germany)
and 125 ng of plasmid per well (24-well plate) according to the manu-
facturer’s protocol and incubated for the indicated periods of time. For
co-transfection of plasmid with miRNA or siRNA, co-complexation
was performed using polyethylenimine (PEI) F25-LMW. Briefly, for
one well (24-well plate), 125 ng of plasmid and 700 ng of siRNA
or miRNA were dissolved in 25 μl of 10 mM Hepes/150 mM NaCl
buffer (pH 7.4). PEI F25-LMW (4.2 μg) was diluted in 25 μl of the
same buffer and, after incubation for 10 minutes, added to the nucleic
acid solution. Complexes were allowed to form during a 30-minute
incubation at room temperature and were then added to the cells.
Plasmids and Luciferase Assay
Plasmids encoding luciferase in front of the Pim-1 3′untranslated
region (3′UTR) or Pim-1 3′UTRwith amutatedmiR-15b seed region
are based on the pGL3 control luciferase reporter vector (Promega,
Mannheim, Germany) and were cloned as described previously [7].
To generate the mutated miR-15b seed region, two point mutations
(C→G) were inserted by polymerase chain reaction (PCR)–directed
mutagenesis and the result was verified by DNA sequencing. HCT-
116 cells were seeded in a 24-well plate at a density of 3 × 104 cells/
well and co-transfected with plasmid (pGL3 Pim-1 3′UTR or pGL3
Pim-1 3′UTRmut) and miR-15b seed, miR-15b, siPim-1, or, as neg-
ative control, siEGFP using PEI F25-LMW as described above. After
72 hours, luciferase activity was determined. Cells were lysed in 24-well
plates with 100 μl of lysis buffer (Promega). Lysate (10 μl) was then
mixed with 25 μl of luciferase substrate (pjk, Kleinblittersdorf,
Germany) and immediately measured using an FB 12 Luminometer
(Berthold, Bad Wildbach, Germany).
Treatment of Cells with the Pim-1 Inhibitor KH-CARB13
and Cytostatics
A 20 mg/ml stock solution of the Pim-1 kinase inhibitor KH-
CARB13 (PubChem CID: 54613583; compound 20 in [20]) was
prepared in DMSO and then further diluted in phosphate-buffered
saline (PBS) or medium; 1 × 103 HCT-116 or 3 × 103 LS174T
cells/well were seeded in a 96-well plate and incubated under standard
conditions. For treatment, the medium was aspirated and replaced
by 100 μl of IMDM/10% FCS medium containing KH-CARB13
at the indicated concentrations, and cells were incubated at 37°C for
72 hours.
5-FU, oxaliplatin (L-OHP), and docetaxel (DTX) stock solutions in
0.9% NaCl were obtained from the University Hospital Leipzig. The
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active irinotecan metabolite 7-ethyl-10-hydroxycamptothecin (SN38)
was purchased from Sigma-Aldrich (Taufkirchen, Germany) and dis-
solved in DMSO, before further dilution in PBS. For the analysis of
5-FU–mediated Pim-1 up-regulation, 3.5 × 105 HCT-116 cells/well
were seeded in a six-well plate and incubated under standard con-
ditions. Then, the medium was replaced by 2 ml of IMDM/10%
FCS containing 1 or 3 μM 5-FU, and cells were incubated at 37°C
for 24 hours. For cell viability assays, 5 × 102 HCT-116 cells were
seeded in a 96-well plate, transfected as described above, and incubated
at 37°C for 24 hours. After aspiration of medium, 100 μl of IMDM/
10% FCS medium containing 5-FU, L-OHP, SN38, or DTX at indi-
cated concentrations was added, and cells were incubated for 48 hours
(DTX) or 72 hours (5-FU, L-OHP, SN38). For luciferase reporter
assays, 3 × 104 HCT-116 cells were seeded in a 24-well plate and trans-
fected as described above. After 48 hours, the medium was replaced by
500 μl of 1 or 3 μM 5-FU diluted in IMDM/10% FCS, and cells were
incubated at 37°C for 24 hours. To determine repression of miR-15b by
5-FU treatment, 1.2 × 105HCT-116 cells were seeded in a six-well plate.
After 24 hours, mediumwas replaced by 2 ml of IMDM/10% FCS con-
taining 3 μM 5-FU, and cells were incubated for 24 hours at 37°C.
RNA Preparation and mRNA and miRNA Detection by
Quantitative PCR
Total cellular RNA was prepared by phenol/chloroform extraction
using 250 μl of TRI Reagent (Sigma-Aldrich) according to the manu-
facturer’s protocol. miRNA was extracted using mirVana miRNA
Isolation Kit (Applied Biosystems, Darmstadt, Germany) according
to the manufacturer’s protocol. cDNA was transcribed from 1 μg of
RNA using the RevertAid H Minus First Strand cDNA Synthesis Kit
(Fermentas, St Leon-Roth, Germany) as described previously [8]. For
miRNA reverse transcription, specific stem-looped primers were used
as described previously [21]. cDNA was diluted 1:10 with nuclease-free
water. Quantitative PCR was performed in a LightCycler 2.0 (Roche)
using the Absolute QPCR SYBR Green Capillary Mix (Thermo Scien-
tific). All procedures were conducted according to the manufacturers’
protocols with 4.5 μl of cDNA (diluted 1:10), 1 μl of primers (5 μM),
and 5 μl of SYBR Green master mix. A preincubation for 15 minutes
at 95°C was followed by 55 amplification cycles: 10 seconds at 95°C,
10 seconds at 55°C, and 10 seconds at 72°C. Themelting curve for PCR
product analysis was determined by rapid cooling down from 95 to
65°C and incubation at 65°C for 15 seconds before heating to 95°C.
Tonormalize for equalmRNA/cDNAamounts, PCRswith target-specific
and actin-specific primer sets were always run in parallel for each sam-
ple, and target levels were determined by the formula 2CP(target)/2CP(actin)
with CP as the cycle number at the crossing point (0.3).
Western Blot Analysis
Cells were seeded and transfected in six-well plates as described
above. Seventy-two hours after transfection, the medium was removed
and cells were washed once with PBS. Two hundred microliters of
lysis buffer [1mMEDTA, 1%NP-40 in PBS, protease inhibitor cock-
tail (EDTA-free; Roche), Ser/Thr- and Tyr-phosphatase inhibitors
(Sigma-Aldrich)] was added per well and plates were incubated on
ice for 15 minutes. The suspension was transferred to Eppendorf tubes
and sonicated for 20 seconds followed by centrifugation (13,000 rpm,
4°C, 20 minutes). The supernatant was transferred to a new Eppendorf
tube and protein concentration was determined using the Bio-Rad DC
Protein Assay (Bio-Rad, Munich, Germany) according to the manu-
facturer’s protocol. Loading buffer (4×) was added [0.25 mM Tris-HCl
(pH 6.8), 20% glycerol, 10% β-mercaptoethanol, 8% sodium dodecyl
sulfate, and 0.08% bromophenol blue] to yield a 1× concentration.
Forty micrograms of protein was loaded onto 10% polyacrylamide
gels, separated by sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis, and transferred onto a 0.2-μm (survivin) or 0.45-μm (all other
proteins) Immobilon-P Transfer polyvinylidene difluoride (PVDF)
Membrane (Millipore, Billerica, MA). Membranes were blocked with
5% (wt/vol) nonfat dry milk in TBST [10 mM Tris-HCl (pH 7.6),
150mMNaCl, 0.1%Tween 20], washed inTBST, and incubated with
primary antibodies diluted in 3%nonfat drymilk in TBST: anti–phospho-
p21Cip1/WAF1 (antibodies online, Aachen, Germany), anti-survivin
(Epitomics, Burlingame, CA), anti–Pim-1 (Epitomics), anti–α-tubulin
(Sigma-Aldrich), anti-actin (Santa Cruz Biotechnology, Heidelberg,
Germany), anti–c-Myc (Santa Cruz Biotechnology), anti-Bax (Cell Sig-
naling Technology, Danvers, MA), anti-Puma (Cell Signaling Technol-
ogy), or anti–Bcl-xL (Cell Signaling Technology). The other antibodies
were diluted in 5% BSA in TBST: anti–phospho-p38 (Thr180/Tyr182)
mitogen-activated protein kinase (MAPK), anti–phospho-stress-activated
protein kinase/c-jun N-terminal kinase (SAPK/JNK) (Thr183/Tyr185),
anti–phospho-p44/42 MAPK [extracellular signal-regulated kinase 1/2
(Erk1/2) Thr202/Tyr204], anti–phospho-STAT3 (Tyr705), or anti–
phospho-STAT3 (Ser727; all from Cell Signaling Technology). Blots
were incubated overnight at 4°C, washed in TBST, and incubated for
1 hour with HRP-coupled goat anti-rabbit IgG (Cell Signaling Technol-
ogy) or HRP-coupled goat anti-mouse IgG (Santa Cruz Biotechnology)
in TBST containing 3% nonfat dry milk. After washing again, bound
antibodies were visualized by enhanced chemiluminescence (ECL Kit;
Thermo Scientific). Scanned bands were quantitated using ImageJ
(National Institutes of Health, Bethesda, MD).
Proliferation and Soft Agar Assay
For the assessment of anchorage-dependent proliferation, cells were
seeded and transfected in 96-well plates as described above. At the time
points indicated, the number of viable cells was determined using a
colorimetric assay. Briefly, the medium was aspirated and 50 μl of a
1:10 dilution of Cell proliferation Reagent WST-1 (Roche Molecular
Biochemicals, Mannheim, Germany) in serum-free medium was added
to the cells before incubation for 1 hour at 37°C. The absorbance at
450 nm was measured using a Dynex MRX microplate reader (Pegasus
Scientific Inc, Rockville, MD).
For studying anchorage-independent proliferation, soft agar assays
were performed as described previously [22]. Briefly, cells were seeded
in six-well plates and transfected as described above. Twenty-four
hours later, cells were trypsinized and counted. Cells (2 × 105) in
0.35% agar (Carl Roth, Karlsruhe, Germany) were layered on top of
1 ml of a solidified 0.6% agar in a six-well plate. The bottom layer
contained 7.5% FCS and the top layer contained 8.5% FCS, respec-
tively. After incubating for 1 week, colonies >50 μm in diameter were
counted by at least two blinded investigators.
Apoptosis Assay
To determine the rate of apoptosis, the Caspase-Glo 3/7 Assay
(Promega) was used. HCT-116 cells (5 × 102) were seeded in a 96-well
plate, transfected as described above, and incubated at 37°C for
72 hours or for 24 hours when followed by a 72-hour treatment with
5 μM 5-FU. The medium was aspirated and 50 μl of caspase substrate,
diluted 1:5 in serum-free medium, was added to the cells. After in-
cubation for 1 hour at room temperature in the dark, luminescence
was measured using a Fluostar Optima reader (BMG Labtec, Jena,
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Germany). To normalize for differences in cell densities, a WST-1 assay
was performed in parallel on the same plate.
Mouse Xenograft Models
Athymic nude mice (Hsd:Athymic Nude-Foxn1nu, 6–8 weeks of
age) were obtained from Harlan Winkelmann (Borchen, Germany)
and kept at 23°C in a humidified atmosphere and a 12-hour light/
dark cycle, with standard rodent chow and water ad libitum. Ex-
periments were performed according to the national regulations and
approved by the Regierungspräsidium Giessen (Giessen, Germany).
For tumor establishment, 1.5 × 106 HCT-116 cells in 150 μl of PBS
were injected subcutaneously (s.c.) into both flanks of the mice. When
the solid tumors reached a volume of 40 to 50 mm3, mice were ran-
domized into specific treatment, negative control treatment, and non-
treatment groups (n = 12 tumors per group). SiRNAs were complexed
with PEI F25-LMW essentially as described previously [22]. Briefly,
10 μg of siRNA was dissolved in 75 μl of 10 mM Hepes/150 mM
NaCl (pH 7.4) and incubated for 10 minutes. Fifty micrograms of
PEI F25-LMW was dissolved in the same buffer and, after incuba-
tion of 10 minutes, mixed with the siRNA solution. The complexes
were aliquoted and stored frozen [22]. Before use, the complexes were
thawed and allowed to incubate for 1 hour at room temperature. For
local treatment, 3 μg of PEI F25-LMW–complexed siRNA was ad-
ministered every 2 to 3 days by intratumoral (i.t.) injection. For sys-
temic treatment, 10 μg of PEI F25-LMW–complexed siRNA was
administered every 2 to 3 days by intraperitoneal (i.p.) injection, de-
scribed previously as optimal [22]. Where applicable, 70 or 40 mg/kg
5-FU in PBS was injected i.p. every 3 to 4 days. Tumor volumes were
monitored every 2 to 3 days. Mice were sacrificed 1 day after the last
treatment, and tumors were removed. Pieces of the tumor tissue where
either fixed immediately with 10% paraformaldehyde for paraffin
embedding or snap frozen for RNA preparation.
Immunohistochemistry
Paraffin-embedded sections were immunohistochemically stained
for Pim-1 essentially as described previously [22]. Briefly, sections were
deparaffinized with xylene and rehydrated with graded alcohols.
Antigen retrieval was accomplished by incubation in 1 mM EDTA
(pH 8.0) at 90 to 95°C temperature for 15 minutes. Endogenous per-
oxidases were inactivated with 0.3% hydrogen peroxide at 4°C for
30 minutes. Sections were blocked with 10% normal goat serum in
phosphate-buffered saline with Tween 20 (PBST)/2% BSA for 1 hour at
room temperature before incubation with rabbit monoclonal anti–Pim-1
antibodies (Epitomics) in PBST overnight at 4°C in a wet chamber.
After washing in PBST, a 1:1000 solution of biotinylated horse anti-
rabbit IgG (Vector Laboratories, Burlingame, CA) in PBSTwas applied
for 1 hour. For visualization, sections were incubated with a streptavidin-
biotin-peroxidase complex (ABCKit; Vector Laboratories) for 30min-
utes before washing and incubation with 3,3′-diaminobenzidine.
In the presence of immunoreactivity, a brownish color was obtained
on the section and the overall staining intensities were ranked from
0 (no staining) to 4 (strong staining).
Statistics
Statistical analyses were performed by Student’s t test or one-way
analysis of variance/Tukey multiple comparison post-test, and signifi-
cance levels are *P < .03, **P < .01, ***P < .001, and #not significant.
Values are shown as means ± SEM.
Results
siRNA-mediated Knockdown of Pim-1 in Colon Carcinoma
Cell Lines
Three Pim-1–specific siRNAs were analyzed in HCT-116 colon
carcinoma cells. While all siRNAs revealed a >50% knockdown efficacy
compared to the negative control siRNA against an irrelevant gene
(luciferase), the Pim-1–specific siRNA 1491 led to the most profound
reduction of Pim-1 mRNA levels and was selected for subsequent
experiments (Figure W1A). In all three colon carcinoma cell lines,
siRNA transfection resulted in a 70% to 80% knockdown of Pim-1
mRNA (Figure 1A), which was paralleled by low residual protein levels
as determined by Western blot analysis (Figure 1B).
Antiproliferative and Proapoptotic Effects upon
Pim-1 Knockdown
For the assessment of the functional relevance of Pim-1 expression
in colon carcinoma cells, we initially analyzed two key features of
tumor cells: accelerated proliferation and evasion from apoptosis.
Upon siPim-1 transfection, a marked reduction of the anchorage-
dependent cell proliferation was detected in all cell lines tested (Fig-
ure 1C and data not shown). The comparison of different siRNAs in
two cell lines further revealed that the most profound Pim-1 knock-
down also resulted in the most prominent inhibition of proliferation
(Figure W1B). The antiproliferative effects of the siRNA-mediated
Pim-1 knockdown were confirmed in soft agar assays, with a >50%
reduction in HCT-116 cell colony formation and the formation of
smaller colonies compared to negative control–transfected or wild-type
cells (Figure 1D). To test whether this antiproliferative effect is at
least in part due to elevated apoptosis, we analyzed the activation of
caspase-3/7, representing an early event in apoptosis. Notably, in
HCT-116 cells, caspase-3/7 showed a statistically significant ∼1.5-fold
increased activity upon Pim-1 knockdown (Figure 2A), demonstrating
an antiapoptotic role of Pim-1. To confirm our findings independently
of RNAi-mediated knockdown strategies, the newly described Pim-1
kinase inhibitor KH-CARB13 was employed [20]. Increasing con-
centrations of KH-CARB13 led to a dose-dependent decrease in the
viability of LS174T and HCT-116 cells (Figure 2B). Concomitantly,
KH-CARB13 led to a moderate but still statistically significant increase
in caspase-3/7 activity (Figure 2C ), confirming the results obtained
after siRNA-mediated Pim-1 knockdown. Taken together, our re-
sults establish a proliferative and antiapoptotic role of Pim-1 in colon
carcinoma cells.
Antitumor Effect upon Local Delivery of Pim-1 siRNA
To test the functional relevance of Pim-1 more rigorously in an
in vivo situation, we explored a therapeutic, siRNA-mediated knock-
down of Pim-1 in s.c. tumor xenografts. To this end, HCT-116 cells
were injected s.c. in athymic nude mice, and upon establishment
of solid tumors, mice were randomized into treatment and control
groups. Specific or negative control siRNAs were complexed in poly-
meric nanoparticles based on low molecular weight PEI (PEI F25-
LMW) as described previously [22], and 3 μg of siRNA was injected
i.t. three times a week for a period of 14 days. In the case of untreated
tumors, a rapid ∼12-fold increase of tumor volume was observed,
while the i.t. injection of PEI/negative control siRNA complexes led
to a slight, statistically nonsignificant inhibition of tumor growth, prob-
ably due to some mechanic disruption of the tumor tissue by the in-
jection as observed previously [8]. Notably, however, upon delivery
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Figure 1. Pim-1 inhibition exerts antiproliferative and proapoptotic effects. (A, B) siRNA-mediated Pim-1 knockdown in colon carcinoma cell
lines, as determined on Pim-1mRNA (A) and protein (B) levels. A representative example of aWestern blot is shown. (C, D) Pim-1 knockdown
leads to antiproliferative effects in anchorage-dependent growth, as determined by WST-1 assay (C), and (D) anchorage-independent soft
agar colony formation. The right panel shows two representative images of colonies.
Figure 2. Pim-1 knockdown leads to induction of apoptosis. (A) Elevated caspase-3/7 activity after siPim-1 delivery. (B) Pim-1 inhibitor
KH-CARB13 leads to dose-dependent reduction of cell viability in HCT-116 and LS174T colon carcinoma cells and (C) increased apoptosis.
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of PEI-complexed Pim-1–specific siRNA, tumor volumes were sig-
nificantly reduced by ∼50% (P < .01) compared to negative control–
treated tumors (∼65% reduction compared to untreated tumors;
Figure 3A). In agreement with the previously shown PEI-mediated
delivery of siRNAs into tumor cells [22], the immunohistochemical
staining of the tumor tissues upon termination of the experiments
revealed a decrease in Pim-1 expression in PEI/siPim-1–treated tumors
compared to the control groups (Figure 3B), thus confirming that the
observed antitumor effects were based on Pim-1 targeting.
Pim-1 Knockdown Sensitizes Colon Carcinoma Cells to 5-FU
While we show that a Pim-1 knockdown exerts antitumor effects,
a clinically more relevant scenario may rely on a combination of Pim-1
targeting and established chemotherapy and the systemic rather than
i.t. application of siRNAs. We therefore chose a combinatorial ap-
proach of systemic PEI/siPim-1 delivery and 5-FU treatment. 5-FU
was selected because it is part of established treatment regimens
(FOLFOX, FOLFIRI) and in vitro experiments suggested possible
synergistic effects (see below), and it was used here as single cytostatic
to precisely analyze its combination with Pim-1 knockdown. Upon
establishment of HCT-116 tumor xenografts, mice in the treatment
groups were i.p. injected three times a week with 10 μg of PEI/siPim-1
or PEI/siCtrl, alone or in combination with 70 mg/kg 5-FU in PBS
(i.p., twice a week). Tumors grew rapidly and while, as expected, no
difference in tumor size was observed upon PEI/siCtrl treatment, the
same was true for PEI/siPim-1 treatment (Figure 3C , left). In contrast,
within 1 week of 5-FU treatment (for correct comparison, combined
with the PEI-complexed negative control siRNAs), ∼40% reduced
tumor volumes were observed. More importantly, however, when
combining PEI/siPim-1 and 5-FU treatment, tumor volumes reached
only ∼30% of mouse groups treated with PEI/siCtrl or PEI/siPim-1
alone and statistically significant tumor growth inhibition was achieved
(Figure 3C , left). This indicates a synergistic effect of PEI/siRNA-
mediated Pim-1 knockdown and 5-FU treatment.However, after 1week,
mice that received 5-FU treatment died after losing weight, swelling of
the mouth, and showing behavioral alterations. This prompted us to
repeat the experiment using a lower dosage of 40 mg/kg 5-FU in PBS
(i.p., twice a week). Throughout the whole treatment period, the mouse
body weights remained stable and no behavioral alterations or other
signs of discomfort were observed (data not shown). Again, untreated
tumors grew rapidly, and despite prolonged tumor treatment for 12 days,
no difference in tumor volumes was observed between PEI/siCtrl and
PEI/siPim-1 treatment (Figure 3C , right). This confirmed that an
siRNA-mediated Pim-1 knockdown is insufficient to induce antitumor
effects in this tumor model. The treatment of mice with 5-FU (again,
for appropriate comparison in combination with the PEI-complexed
negative control siRNAs) led to an ∼20% decrease in tumor growth.
More importantly, only the combination of PEI/siPim-1 and 5-FU treat-
ment led to a statistically significant decrease in tumor volumes to
∼60% of mouse groups treated with PEI/siCtrl or PEI/siPim-1 alone,
confirming the synergistic effect of PEI/siRNA-mediated Pim-1 knock-
down and 5-FU treatment (Figure 3C , right).
Surprisingly, the subsequent immunohistochemical staining of the
tumor tissues for Pim-1 revealed slightly elevated Pim-1 levels in all
5-FU treatment groups, which possibly obscured the RNAi knock-
down effects (Figure 3D, left). To further explore this finding, we
exposed HCT-116 cells in vitro to 5-FU and indeed detected an
increase of Pim-1 mRNA levels in a concentration-dependent manner
(Figure 3D, right) that peaked 24 hours after the start of treatment.
In agreement with our findings regarding a proliferative and anti-
apoptotic role of Pim-1 (see above), we found the cells to grow more
densely for the first 24 hours of 5-FU exposure (Figure 3D, right) before
the onset of the expected cytotoxic 5-FU effects. Keeping in mind that
mice were sacrificed 24 hours after the last 5-FU treatment, these
in vitro results are in line with the observed elevation in Pim-1 levels
in the dissected tumors.
The effect of Pim-1 levels on the sensitivity of colon carcinoma cells
toward single chemotherapeutics that are part of established combina-
tions in colon carcinoma therapy was then characterized more closely
in vitro. Indeed, after 72 hours the double treatment of HCT-116
cells with siPim-1 and 5-FU revealed synergistic effects on tumor cell
cytotoxicity at low 5-FU concentrations, as determined by a shift of
the upper part of the 5-FU dose-response curve to the left, i.e., toward
lower 5-FU concentrations, and a more than three-fold decrease in
the IC50 (Figure 4A). In contrast, no differences were observed upon
treatment of the cells with other cytostatics relevant in colon carci-
noma therapy schemes, namely, oxaliplatin or the active metabolite
of irinotecan, SN38 (Figure W2). The same was true for the cytotoxic
antimicrotubule agent docetaxel. The increase in cellular 5-FU sen-
sitivity upon Pim-1 knockdown thus confirmed the in vivo results
(see Figure 3C ). Apoptosis assays revealed that it is at least in part
due to a slightly more profound increase in 5-FU–mediated apoptosis
upon siPim-1 treatment (∼1.7 vs 1.4-fold; compare 5-FU treatment
bars in Figure 4B).
5-FU Effects on Pim-1 Expression Are Mediated by miR-15b
To address the 5-FU–mediated up-regulation of Pim-1 expression
in more detail, we speculated that miRNAs may be involved. In silico
analyses (TargetScan 6.1) identified the 3′UTR of Pim-1 as a putative
target of miR-15b. Indeed, in a reporter gene assay with the intact
Pim-1 3′UTR, the transfection with miR-15b markedly reduced
luciferase activity to 60% of the siEGFP negative control, whereas
no effect was observed in the case of the Pim-1 3′UTR with mutated
miR-15b seed (Figure 4C , left vs right panel). This finding points
to a direct regulation of Pim-1 by miR-15b. SiPim-1, which binds
Pim-1 3′UTR in another position than miR-15b, was able to reduce
reporter gene activity of both constructs drastically. Zhou et al. had
reported previously that miR-15b is downregulated by 5-FU [23].
Indeed, a 40% reduction in miR-15b levels was found in our ex-
periments (Figure 4D, left). The hypothesis that this 5-FU–mediated
miR-15b down-regulation is responsible for Pim-1 elevation was tested
using the reporter gene constructs. Transfection of the constructs and
subsequent treatment with 5-FU revealed, in accordance with our pre-
vious results, a 5-FU concentration-dependent increase in luciferase
activity (Figure 4D, right, center bars). In contrast, no increase in lucif-
erase activity was observed in the case of the mutant miR-15b seed,
supporting that the 5-FU–mediated up-regulation of Pim-1 is indeed
critically dependent on miR-15b.
Downstream Effects of Pim-1 Knockdown
To unravel the molecular mechanisms behind the antitumor effects
of Pim-1 knockdown in colon carcinoma cells, we analyzed several
proteins that have either been described as downstream effector mole-
cules of Pim-1 kinase activity or that are involved in cell survival, apop-
tosis pathways, or migration. The cell cycle regulator p21Cip1/WAF1 is
a known target of Pim-1 in leukemia cells [24]. Indeed, upon Pim-1
knockdown, levels of p21Cip1/WAF1 phosphorylated at the Pim-1 target
site Thr145 were markedly reduced by ∼75% compared to the negative
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Figure 3. Antitumor effect of PEI/siPim-1 treatment in s.c. HCT-116 colon carcinoma xenograft mouse models. (A) Intratumoral injection
of PEI/siPim-1 complexes results in decreased tumor growth compared to treatment with negative control (PEI/siCtrl) or untreated mice.
(B) Immunohistochemical staining for Pim-1 shows decreased Pim-1 expression in tumors treated with siPim-1. (C) Mice treated sys-
temically with PEI/siPim-1 complex are more sensitive toward 5-FU therapy. Upon treatment with 70 (left) or 40 mg/kg 5-FU (right), more
profound and statistically significant antitumor effects are observed in the PEI/siPim-1 + 5-FU group compared to mice treated with
5-FU + PEI-complexed negative control siRNA. (D) Left: Immunohistochemical staining of the tumor tissues for Pim-1 reveals elevated
levels of Pim-1 in 5-FU treatment groups. Right: Exposure of HCT-116 cells to 5-FU in vitro leads to an early increase in Pim-1 mRNA levels
(left) and elevated cell growth (right).
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controls (Figure 5A, left, andWestern blot, upper panel ). In contrast, no
change in mRNA expression of p21Cip1/WAF1 was observed (Figure 5A,
center panel ) indicating that Pim-1 acts posttranslationally through
phosphorylation rather than affecting p21Cip1/WAF1 expression.
The antiapoptotic protein survivin has been described previously
to be overexpressed in a variety of tumor entities and to be associated
with poor prognosis [25]. Upon Pim-1 knockdown, survivin was
reduced on the mRNA and protein level, respectively (Figure 5A, right
panel and Western blot). STAT3 has been described previously to be
involved in the regulation of Pim-1 [3,4] and of survivin expression
[26]. Upon Pim-1 knockdown, a down-regulation of STAT3 phos-
phorylation at Tyr705 was detected, which is in contrast to Chang
et al. who found that STAT3 phosphorylation in prostate and pan-
creatic carcinomas was mediated by Pim-3 rather than Pim-1 [27].
Notably, in our experiments, a reduction of STAT3 phosphorylation
at Ser727 was observed as well. This decrease was even more pro-
nounced than the Tyr705 phosphorylation (Figure 5B) and has not
been described before. Moreover, Pim-1 knockdown also led to some
other changes (Figure 5B). Seventy-two hours after siPim-1 transfection,
phospho-JNK1 and phospho-JNK2 levels were decreased, whereas
P-p38 and P-Erk1/2 levels remained unchanged. We furthermore
analyzed the oncogenic transcription factor c-Myc and the tumor sup-
pressor p53, whose stability had been identified previously in mantle
cell lymphoma to be affected by Pim-1 indirectly through p53 E3
ubiquitin ligase Mdm2 [28]. While we observed an only slight decrease
in c-Myc levels 72 hours after siPim-1 transfection, a more profound
decrease in p53 expression was detected. Finally, we tested E-cadherin
because it is a marker for anchorage-dependent growth and has been
Figure 4. Additive effect of Pim-1 knockdown and 5-FU in HCT-116 colon carcinoma cells. (A) Knockdown of Pim-1 through siRNA results in
sensitization of HCT-116 cells to 5-FU exposure 72 hours after the start of treatment [see left shift of the upper part of the dose-response
curve and (insert) the calculated IC50 values]. (B) 5-FU–mediated induction of caspase-3/7 is increased by siRNA-mediated knockdown of
Pim-1, reaching statistical significance. (C) Pim-1 is directly regulated by miR-15b (compare center bars in each panel; siPim, positive con-
trol). (D) The up-regulation of Pim-1 by 5-FU is mediated by miR-15b. Left: 5-FU treatment leads to the down-regulation of miR-15b. Right:
The Pim-1 3′UTR is a target of miR-15b, as determined by the activity of a luciferase reporter gene–Pim-1 3′UTR fusion construct. Luciferase
activity is increased upon 5-FU treatment (center bars), while this effect is lost upon the introduction of mutations in the miR-15b seed
sequence (right bars).
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shown to be strongly downregulated in an HCT-116 p21Cip1/WAF1
knockout cell line [29]. Indeed, we observed markedly decreased
E-cadherin levels upon Pim-1 knockdown, thus linking p21Cip1/WAF1
phosphorylation, rather than p21Cip1/WAF1 expression, to E-cadherin
levels. Key findings from the siRNA-mediated Pim-1 knockdown
experiments were confirmed by the Pim-1 inhibitor KH-CARB-13
(Figure 5C ). Upon incubation of cells with 2 μM inhibitor, a down-
regulation of P-STAT3 (with a concomitant decrease in Pim-1 levels),
P-p21, c-Myc, and E-cadherin was observed.
Since our results show that a Pim-1 knockdown leads to the in-
duction of apoptosis, we wondered whether apoptosis-related proteins
other than the proapoptotic protein Bad, which has already been estab-
lished as a Pim-1 phosphorylation target, may be affected by Pim-1.
Interestingly, Western blot analysis revealed the proapoptotic pro-
tein Puma, whose gene is a direct target of p53, to be downregulated
upon Pim-1 inhibition, while levels of proapoptotic Bax were ele-
vated (Figure 5D). In line with the induction of apoptosis, the anti-
apoptotic Bcl-xL was found to be decreased in Pim-1 knockdown cells
(Figure 5D).
Discussion
In cardiomyocytes, Pim-1 has important functions in facilitating cell
survival under stress [30], whereas its overexpression in tumor cells
contributes to malignant transformation, tumor progression, and
poor prognosis. While this has been established in hematopoietic
malignancies and prostate cancer, little is known about the functional
relevance of Pim-1 and the underlying molecular mechanisms in
colon carcinoma.
We show here that Pim-1 is embedded in a complex regulatory
network of mitogenic and antiapoptotic signals (Figure 6). While
STAT3 induces Pim-1 expression, Pim-1 itself can regulate STAT3
activity, thus forming a positive autocrine loop. More specifically,
by direct interaction, Pim-1 can activate Etk/BMX tyrosine kinase
[31], which in turn leads to STAT3 activation by phosphorylation at
Figure 5. Downstream effects of siRNA-mediated Pim-1 knockdown or Pim-1 inhibition in HCT-116 colon carcinoma cells. (A) Upon Pim-1
knockdown, levels of Thr145-phosphorylated p21 are markedly decreased (left), while overall p21 expression remains unchanged as de-
termined on mRNA levels (center). Downstream of Pim-1, survivin mRNA, and protein levels are decreased (right). Western blots show
data from a representative experiment. Since the same lysates were used, one loading control is shown. (B) Analysis of various proteins
involved in signal transduction pathways related to cell survival and adhesion. Differences in expression levels are observed upon Pim-1
knockdown (right bands) compared to negative controls. For details, see text. (C) Effects of KH-CARB-13–mediated Pim-1 inhibitor on
downstream signaling molecules confirm knockdown results. (D) Alterations in the levels of proapoptotic and antiapoptotic proteins upon
Pim-1 knockdown.
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Tyr705 [32]. In the tumor context, this leads to the constitutive ac-
tivation of STAT3, and indeed, we found reduced STAT3 P-Tyr705
levels upon RNAi-mediated knockdown of Pim-1 expression in colon
carcinoma. Our results are confirmed by the inhibitor KH-CARB1,
which has been described only recently and is used here for the first
time in the context of solid tumors. While it has been shown to
be largely specific for Pim-1, further improvement with regard to
specificity and IC50 will remain a matter of further investigation
(F. Bracher, personal communication). In addition to Tyr705 phos-
phorylation of STAT3, we reveal here that STAT3 P-Ser727 levels are
regulated by Pim-1 as well. The consequences of Ser727 phosphory-
lation on STAT3 activity and DNA binding capacity are discussed
controversially with regard to transcriptional activation or inactivation.
However, in invasive colorectal cancer, activated STAT3 and STAT3-
inducible genes are found to be overexpressed and are associated with
increased proliferation and lymph node metastasis [33]. Additionally,
simultaneous Tyr705 and Ser727 phosphorylation of STAT3 was found
to be essential for oncogenic transformation mediated by the GTPase
RhoA [34]. Taken together, this emphasizes the relevance of Pim-1 for
STAT3 activation. Beyond Etk/BMX, the MAPK family member
JNK1 may represent another possible linker between Pim-1 and
STAT3 by mediating STAT3 Ser727 and/or Tyr705 phosphorylation
[35]. In agreement with the above-mentioned autocrine loop, we dem-
onstrate that JNK1 and JNK2 phosphorylation was repressed upon
Pim-1 knockdown. In addition to STAT3, this may be relevant since
there is increasing evidence that in colon carcinoma JNK1 and JNK2
contribute to oncogenesis.
p21Cip1/WAF1 is another target of Pim-1. It is phosphorylated by
Pim-1 at Thr145 [24], thus leading to the disruption of its binding to
proliferating cell nuclear antigen, which in turn is then free to function
as processivity factor in DNA replication. Furthermore, P-Thr145 leads
to retention of p21Cip1/WAF1 in the cytoplasm or its translocation to
the cytoplasm [24]. Nuclear p21Cip1/WAF1 can negatively regulate cell
cycle progression and inhibit the transcriptional activity of STAT3
[36], and the Pim-1–mediated shift of p21Cip1/WAF1 toward a cytosolic
localization consequently reverses these effects. Concomitantly, we
have shown previously that Pim-1 knockdown leads to cell cycle in-
hibition in colon carcinoma cells [7]. Notably, we also observed a
suppression of E-cadherin expression upon Pim-1 knockdown. While
this has also been described for p21Cip1/WAF1 knockout cells [29], our
data suggest that the Pim-1–mediated subcellular shift of p21Cip1/WAF1
may already be sufficient for the regulation of E-cadherin expres-
sion. E-cadherin is a marker for the epithelial phenotype, and loss of
E-cadherin is associated with epithelial-mesenchymal transition leading
to the disruption of cell-cell contacts, increased migration, and con-
sequently metastatic dissemination. However, Pim-1 knockdown in
HCT-116 cells did not result in a loss of cell-cell contacts comparable
to HCT-116 p21Cip1/WAF1 knockout cells (data not shown). This is
in line with the finding that the loss of E-cadherin alone is insufficient
for inducing a change in the cellular phenotype [37], indicating that
other molecular effects, e.g., decreased CXCR4 expression [38], may
be involved as well. While this further supports the therapeutic benefit
of Pim-1 inhibition strategies, their precise impact on migration of
colon carcinoma cells and alterations in the expression patterns of tran-
scription factors, chemokine receptors, adhesion molecules, or matrix
metalloproteases yet remains to be elucidated.
Our results also establish a connection between Pim-1 and a mem-
ber of the inhibitor of apoptosis family of proteins, survivin. Although
barely detectable in adult tissue, survivin is highly expressed in various
tumor entities including colon carcinoma and is associated with ele-
vated cell survival and proliferation, higher tumor grade, poor prog-
nosis, as well as resistance to chemotherapy and radiation (for review,
see [25]). The substantial reduction of survivin expression upon Pim-1
knockdown can be readily explained by the inactivation of STAT3,
since survivin is a target protein of STAT3 [39]. Furthermore, the
c-myc gene is a target of STAT3 [40] and was found to elevate survivin
expression when overexpressed in breast cancer [41]. In fact, besides
being stabilized by Pim-1 phosphorylation [12], oncogenic c-Myc also
Figure 6. Schematic depiction of the downstream pathways of Pim-1.
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synergizes with Pim-1 on the chromatin level, resulting in elevated
c-Myc target gene expression [13]. In lymphoma and prostate carci-
noma, this synergy has been reported to promote tumor onset and
development [42,43], and the direct effect of Pim-1 inhibition on
c-Myc as well as the attenuation of c-Myc–induced effects further
supports the relevance of Pim-1 as a target molecule.
Our study suggests that lowmolecular weight inhibitors of Pim-1 are
promising drugs in colon carcinoma, while RNAi-based strategies offer
the potential to target members of the Pim kinase family with highest
specificity. We have shown previously that polymeric nanoparticles
based on branched low molecular weight PEI, PEI F25-LMW, offer
an efficient and nontoxic delivery platform [22], and the antitumor
effects in our mouse tumor model upon i.t. administration confirm
the bioactivity of PEI/siPim-1 complexes (Figure 3A). Previous bio-
distribution studies have also shown that i.p. injected PEI/siRNA
complexes reach the s.c. tumors, where full-length siRNAs accumulate
[22]; yet, in the HCT-116 xenograft model, no antitumor effects of
PEI/siPim-1 single therapy were observed upon systemic (i.p.) injec-
tion. Still, tumors were significantly sensitized toward 5-FU treatment,
which can be readily explained by the down-regulation of p53 upon
Pim-1 knockdown. Indeed, although being a tumor suppressor, p53
overexpression was found to predict poor sensitivity to high-dose
5-FU chemotherapy in colorectal cancer [44]. Even more important
for the increase in 5-FU sensitivity upon silencing of Pim-1 may be
the Bcl-xL/Bax ratio. Pim-1 knockdown resulted in antiapoptotic
Bcl-xL to be downregulated and proapoptotic Bax to be elevated,
and a smaller Bcl-xL/Bax ratio has been shown to be associated with
increased 5-FU sensitivity in colon carcinoma cells, independent of
p53 status [45]. Interestingly, beyond additive or synergistic effects
as discussed above, the Pim-1 knockdown may also antagonize the
(unwanted) up-regulation of Pim-1 upon 5-FU treatment at early time
points (Figure 3). This effect, newly described here, may also have
obscured the analysis of PEI/siRNA knockdown efficacies in vivo (note
that tumors were taken 24 hours after the last treatment, thus at the
peak time of 5-FU–mediated Pim-1 induction). Thus, our data provide
the basis for a rational combination therapy based on Pim-1 inhibition
and chemotherapy that contains 5-FU.
Certain miRNAs have been shown to regulate Pim-1 expression,
including miR-1 [46] and miR33a [7]. In this study, we identify the
tumor suppressor miRNA miR-15b to directly target Pim-1. MiR-15b
is highly conserved among species and shares its seed sequence with
miR15a and miR-16. Its functional relevance in tumor biology has
been established by the identification of several target genes involved
in apoptosis (e.g., Bcl-2 [47]) and cell cycle (e.g., cyclin E1 [48]), and
it negatively regulates chemotherapy-induced epithelial-mesenchymal
transition [49]. Here, we describe novel functionalities of miR-15b
in the context of Pim-1 inhibition and 5-FU therapy. Notably, mem-
bers of the miR-15/16 family are often underexpressed in tumors and
have already been explored in miRNA replacement therapy. In addi-
tion to the reintroduction of the natural Pim-1 regulatory miR-33a
described recently [7,8], our results now suggest miR-15b as a novel
therapeutic miRNA.
Beyond siRNAs, miRNA replacement therapy extends the set of
inhibitory small RNA molecules. siRNAs are intended to target a
single mRNA by completely complementary base pairing and sub-
sequent target mRNA degradation, thus exhibiting a strong gene
knockdown effect on a single target gene. In contrast, due to the
limited sequence complementarity of miRNAs to their targets and their
inhibitory effect on mRNA translation, one miRNA may well have
several 100 target genes and inhibitory effects mediated by miRNAs
are generally broader and milder. Consequently, although molecularly
less specific, the replacement of a tumor suppressor miRNAmay inhibit
the expression of several oncogenes at once and thus rather address the
concept of tumorigenesis as a pathway disease. In the case of miR-15b,
this may yield (therapeutically beneficial) effects beyond Pim-1 inhibi-
tion, although effects unrelated to the inhibition of Pim-1 or other
established target genes would have to be monitored carefully.
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Figure W1. Characterization of different Pim-1–specific siRNAs (siPim-1). (A) Sequences of three specific siRNAs and their knockdown
efficacies in HCT-116 cells. (B) Antiproliferative effects of siRNAs compared to negative control–treated or untreated HCT-116 (left) or
HT-29 (right) cells.
Figure W2. Pim-1 knockdown does not sensitize HCT-116 colon carcinoma cells to treatment with docetaxel, oxaliplatin, or the active
irinotecan metabolite SN38.
